Table4 Subgroup analyses results
From: Safety and efficiency of stem cell therapy for COVID-19: a systematic review and meta-analysis
Outcomes | Study Types | Effect Size [95%CI] | I2 |
|---|---|---|---|
AE | RCT | 0.57 [0.21, 1.60] | 69% |
NRCT | 0.09 [0.00, 1.62] | – | |
Combined Meta | 0.39 [0.12, 1.33] | 58% | |
Mortality | RCT | 0.26 [0.12, 0.57] | 0% |
NRCT | 0.17 [0.05, 0.57] | 0% | |
Combined Meta | 0.24 [0.13, 0.45] | 0% | |
Length of hospital stay | RCT |  − 0.30 [− 0.81, 0.20] | 61% |
NRCT |  − 0.41 [− 1.35, 0.53] | – | |
Combined Meta |  − 0.34 [− 0.73, 0.05] | 41% | |
Neutrophils | RCT |  − 0.24 [− 0.63, 0.16] | 0% |
NRCT | 0.08 [− 0.60, 0.76] | 0% | |
Combined Meta |  − 0.16 [− 0.50, 0.19] | 0% | |
Lymphocytes | RCT | 0.25 [− 0.15, 0.64] | 0% |
NRCT | 0.41 [− 0.27, 1.10] | 0% | |
Combined Meta | 0.29 [− 0.06, 0.63] | 0% | |
PLT | RCT |  − 0.39 [− 1.33, 0.54] | – |
NRCT |  − 0.09 [− 0.64, 0.46] | 0% | |
Combined Meta |  − 0.17 [− 0.64, 0.30] | 0% | |
CRP | RCT |  − 0.15 [− 0.56, 0.26] | 0% |
NRCT |  − 0.48 [− 1.43, 0.47] | 59% | |
Combined Meta |  − 0.25 [− 0.62, 0.13] | 16% | |
D-dimer | RCT | 0.13 [− 0.24, 0.50] | 0% |
|  | NRCT |  − 0.12 [− 1.15, 0.91] | 39% |
|  | Combined Meta | 0.07 [− 0.26, 0.40] | 0% |